Back to News
Market Impact: 0.4
Xenetic To Acquire Santersus In All-Stock Deal To Advance NET-Focused Pipeline
Source: Nasdaq
M&A & RestructuringHealthcare & BiotechCompany Fundamentals
Xenetic Biosciences and Swiss medical-device company Santersus AG signed a definitive share-exchange agreement to combine their NET-targeting technologies. The transaction is intended to create a Nasdaq-listed, clinical-stage company focused on diseases driven by neutrophils, potentially broadening Xenetic's development platform and investor access.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
XBIO0.55
More News
- California AG Says Paramount-WBD Merger Would Hurt the State
- This AI-picked stock jumps 18% on Amazon’s $8 billion power deal
- US to Sell F-35s to Saudi Arabia in $24.3 Billion Deal
- California AG Bonta on Paramount-Warner Bros., Meta and AI
- Crusoe raises $3.9B to build massive data centers and small modular “AI factories”
- Jensen Huang says Nvidia will sell twice as many chips next year